research Amphiregulin in Fibrotic Diseases and Cancer
Targeting amphiregulin may improve treatment for fibrotic diseases and cancer.
Search
for
Sort by
Research
630-660 / 1000+ results
research Rash from EGFR inhibitors: Opportunities and challenges for palliation
EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
research Level-1 Data From the REDUCE Study and the PCPT Data
Finasteride and dutasteride reduce prostate cancer risk, but finasteride may increase higher-grade cancer risk.
research A new way to restore tumour suppressor function
New treatments may restore cancer-blocking proteins, slow prostate cancer, identify drug targets, and potentially regrow hair.
research Alopecia universalis successfully treated with tofacitinib
Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
research Probing androgen receptor co-factor selectivity profiles: a chemical tool to determine cross-talk between androgen receptor and β-catenin in vivo
PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
research Finasteride in polycythaemia
research Correction to: An evaluation of the federal adverse events reporting system data on adverse effects of 5‑alpha reductase inhibitors
The correction states that the label change for Finasteride was in 2012, leading to more reports of side effects from non-healthcare people.
research JAK inhibition in the treatment of alopecia areata – a promising new dawn?
JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
research Patient Profile and Treatment Characteristics of Early Ritlecitinib Initiators in the US
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research ‘Ritlecitinib: unveiling hair regrowth for alopecia areata’
Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
research Inhibitory effect of M50054, a novel inhibitor of apoptosis, on anti-Fas-antibody-induced hepatitis and chemotherapy-induced alopecia
M50054 may help treat hepatitis and hair loss from chemotherapy.
research Advancing Design Strategy of PROTACs for Cancer Therapy
PROTACs show promise for cancer treatment, but designing them effectively is challenging.
research MP09-16 5-ALPHA REDUCTASE INHIBITORS FOR MALE LOWER URINARY TRACT SYMPTOMS: A COCHRANE SYSTEMATIC REVIEW AND META-ANALYSIS
5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.
research Follow‐up of Adverse Drug Reactions from Peginterferon alfa‐2b—Ribavirin Therapy
Peginterferon alfa-2b and ribavirin therapy for hepatitis C can cause serious side effects, some different from those reported in clinical trials.
research Safety concerns regarding 5α reductase inhibitors for the treatment of androgenetic alopecia
5α reductase inhibitors treat hair loss but may cause sexual side effects and risks.
research Significance of RU58841 as a therapeutic agent effecting androgen receptor molecular interactions in human hair follicles.
RU58841, a substance from France, can potentially block the effects of hormones that cause hair loss and excessive hair growth, performing better than a similar substance, cyproterone acetate.
research A population‐based nested case–control study: the use of 5‐alpha‐reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia
Taking finasteride for benign prostate hyperplasia may increase the risk of osteoporosis, especially at higher doses.
research Aromatase-independent testosterone conversion into estrogenic steroids is inhibited by a 5α-reductase inhibitor
Combining 5α-reductase and aromatase inhibitors may better reduce estrogen levels.
research Adverse Effects of 5-Alpha-Reductase Inhibitors: a narrative review
5-Alpha-Reductase Inhibitors can cause negative side effects.
research Inhibidor janus kinasa como opción terapéutica en alopecia areata. Reporte de caso
Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.
research Antibody Drug Conjugates
Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.
research FCE 28260, a new 5α-reductase inhibitor: In vitro and in vivo effects
FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.
research Tyrosine kinase inhibition and grey hair
Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.
research Effects of Short-Term Finasteride on Apoptotic Factors and Androgen Receptors in Prostate Cancer Cells
Short-term finasteride treatment may lower some cell death factors in prostate cancer cells.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5α-reductases: determinants for different in vivo activities of GI198745 and finasteride in the rat 3 3Abbreviations: r5AR1, rat 5α-reductase 1; r5AR2, rat 5α-reductase 2; and DHT, dihydrotestosterone.
GI198745 is more potent and longer-lasting than finasteride, potentially better for treating hair loss.
research The Effect of 5 -Reductase Inhibitors on Erectile Function
5-alpha-reductase inhibitors may cause a low incidence of erectile dysfunction that decreases over time.
![Synthesis and In Vitro Study of 17β-[N-Ureylene-N,N′-Disubstituted]-4-Methyl-4-Aza-5α-Androstan-3-Ones as Selective Inhibitors of Type I 5α-Reductase](/images/research/d19df8a7-8de6-4430-8a0d-4ffa1f502985/small/15608.jpg)
research Synthesis and in vitro study of 17β-[N-ureylene-N,N′-disubstituted]-4-methyl-4-aza-5α-androstan-3-ones as selective inhibitors of type I 5α-reductase
New compounds were made that effectively block a specific enzyme related to androgen conditions.
research Clinical response to adjunctive platelet-rich plasma injections in a patient with alopecia universalis on oral tofacitinib
A woman with severe hair loss saw significant hair regrowth after adding platelet-rich plasma injections to her treatment with tofacitinib.